MedTrace Logo

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

NCT03677960 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-07-24

No results posted yet for this study

Summary

This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection

Conditions

  • HSIL, High-Grade Squamous Intraepithelial Lesions
  • Human Papilloma Virus Infection
  • HIV Infection
  • Anal Cancer
  • Anus Neoplasm

Interventions

DRUG

Topical ABI-1968 cream

Multiple doses of Topical ABI-1968 Cream administered by the Investigator in the clinic up to Day 29

Sponsors & Collaborators

  • Antiva Biosciences

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
27 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-17
Primary Completion
2019-06-30
Completion
2019-06-30
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03677960 on ClinicalTrials.gov